Sempere Lorenzo F, Keto Jessica, Fabbri Muller
Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, MI 49503, USA.
Comprehensive Breast Center, Mercy Health Saint Mary's, Grand Rapids, MI 49503, USA.
Cancers (Basel). 2017 Jun 24;9(7):71. doi: 10.3390/cancers9070071.
Soon after the discovery of microRNAs over 15 years ago, a myriad of research groups around the world sought to develop clinical applications in breast cancer for these short, noncoding, regulatory RNAs. While little of this knowledge has translated into the clinic, the recent research explosion on cell-to-cell communication via exosomes and other extracellular vesicles has rekindled interest in microRNA-based clinical applications. microRNAs appear to be a preferential and important cargo of exosomes in mediating biological effects in recipient cells. This review highlights recent studies on the biology of exosomal microRNAs (exo-miRNAs) and discusses potential clinical applications. From a diagnostic perspective, circulating exo-miRNAs may represent breast cancer cell content and/or tumor microenvironmental reactions to cancer cell growth. Thus, serum or plasma analysis of exo-miRNAs could be useful for early disease detection or for monitoring treatment response and disease progression. From a therapeutic perspective, exo-miRNAs derived from different cell types have been implicated in supporting or restraining tumor growth, conferring drug resistance, and preparing the metastatic niche. Strategies to interfere with the loading or delivery of tumor-promoting exo-miRNAs or to replenish tumor-suppressive miRNAs via exosomal delivery are under investigation. These recent studies provide new hope and opportunities, but study design limitations and technical challenges will need to be overcome before seriously considering clinical application of exo-miRNAs.
15年多前发现微小RNA后不久,世界各地众多研究团队就试图开发这些短链非编码调节RNA在乳腺癌中的临床应用。虽然这些知识很少转化为临床应用,但最近关于通过外泌体和其他细胞外囊泡进行细胞间通讯的研究热潮,重新燃起了人们对基于微小RNA的临床应用的兴趣。微小RNA似乎是外泌体在介导受体细胞生物学效应中的一种优先且重要的货物。这篇综述重点介绍了外泌体微小RNA(外泌体-miRNA)生物学的最新研究,并讨论了潜在的临床应用。从诊断角度来看,循环中的外泌体-miRNA可能代表乳腺癌细胞成分和/或肿瘤微环境对癌细胞生长的反应。因此,对外泌体-miRNA进行血清或血浆分析可能有助于早期疾病检测或监测治疗反应及疾病进展。从治疗角度来看,来自不同细胞类型的外泌体-miRNA已被证明与支持或抑制肿瘤生长、赋予耐药性以及准备转移微环境有关。干扰促肿瘤外泌体-miRNA的装载或递送,或通过外泌体递送补充肿瘤抑制性miRNA的策略正在研究中。这些最新研究提供了新的希望和机会,但在认真考虑外泌体-miRNA的临床应用之前,还需要克服研究设计上的局限性和技术挑战。